Alzheimer’s drug coverage may be delayed by up to 18 months

Access to coverage for a new Alzheimer’s drug could be delayed by as much as 18 months due to ongoing price negotiations and decisions by provincial drug plans. This delay highlights the complexities involved in approving and funding new treatments despite regulatory approval.

Originally published by gnews